Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Snehal G. Thakkar"'
Autor:
Laura Benjamin, Mark Uhlik, Frederick L Baehner, Jessica Aldrich, Luka Ausec, Gargi D Basu, Janine LoBello, Snehal G Thakkar, Matthew Halbert, Patrick Eimerman, Cynthia A Flannery, Nishitha Therala, David W Hall, Daniel Pointing, Lea Vohar, Roman Lustrik, Seema Iyer
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/7457c363e7264209934d662481b7fc48
Autor:
Deborah Josefson, David W. Hall, Jess Hoag, Ariane Kemkes, Janine LoBello, Snehal G. Thakkar, Gargi Basu
Publikováno v:
Cancer Research. 83:2150-2150
Background Previous work has shown that young females, who present with genomically-stable, poorly-differentiated, diffuse gastric cancer harbor CLDN18/ARHGAP26 fusions more often than older individuals with intestinal type or non-diffuse gastric can
Autor:
Paul Elson, Toni K. Choueiri, Snehal G. Thakkar, Ming Zhou, Ronald M. Bukowski, Brian I. Rini, Rony M. Abou-Jawde, Tarek Mekhail, Rachid Baz, Jorge A. Garcia
Publikováno v:
Annals of Oncology. 18:249-255
Purpose: To identify prognostic factors (PF) for long-term survival in metastatic renal cell carcinoma (RCC) patients. Methods: We retrospectively reviewed a metastatic RCC database at the Cleveland Clinic Foundation consisting of 358 previously untr
Autor:
Paul Elson, Snehal G. Thakkar, Lisa Rybicki, David M. Peereboom, Daniel J. Lindner, Ernest C. Borden, Thomas Olencki, Barbara S. Jacobs
Publikováno v:
Journal of Interferon & Cytokine Research. 26:800-803
Preclinical studies had determined that tamoxifen and interferon-alpha2b (IFN-alpha2b) synergistically inhibited growth of both estrogen-receptor positive and negative murine tumor xenografts and had combined antiangiogenic effects and that tamoxifen
Publikováno v:
Current Oncology Reports. 8:108-113
The endothelins (ETs), which include ET-1, ET-2, ET-3, and their receptors ET-A and ET-B, play a major role in tumor growth, proliferation, apoptosis, angiogenesis, and bone metastasis. Atrasentan is a novel and selective inhibitor of ET-1 and ET-A.
Autor:
Mohamad A. Hussein, Snehal G. Thakkar, James Keaton Smith, A. Licata, Carlos M. Isada, M. Richmond, Janice Reed, J. W. Tomford, M. A. Karam, Kristin Englund, C. Hatch
Publikováno v:
Medical Oncology. 23:51-56
Osteonecrosis of the jaw has been linked with bisphosphonate use in breast cancer and multiple myeloma patients. We report 17 cases of patients with plasma cell dyscrasia being treated with bisphosphonate who developed osteonecrosis/osteomyelitis of
Autor:
Günter Waxenecker, Ronald M. Bukowski, Michael J. Clemente, Meagan Roddy, Emilio D. Poggio, Gottfried Himmler, Snehal G. Thakkar, Donald E. Hricik, Peter S. Heeger, Hans Loibner
Publikováno v:
Transplantation. 80:297-302
Background.Thepresenceofalloantibodiesand/oralloreactiveTcellsinapatientpriortoatransplantcanimpactgraft outcome. Environmental factors, including therapeutic vaccinations, may influence the strength and/or specificity of alloimmunity. Methods. To ad
Autor:
Stephen J. Sup, Snehal G. Thakkar, Carlos Alemany, Paul Elson, Roxanne Steinle, Serena Malhi, Brad Pohlman, Eric D. Hsi
Publikováno v:
Journal of Clinical Oncology. 23:3773-3779
Purpose Although most classical Hodgkin's lymphoma (CHL) patients are cured, a significant minority fails primary therapy and may die as a result of their disease. Age, stage, and other basic clinical and laboratory parameters, which comprise the Int
Autor:
Lisa Rybicki, Robert M. Dean, Brad Pohlman, Anjali S. Advani, Stephen D. Smith, John Sweetenham, Ronald Sobecks, Matt Kalaycio, Brian J. Bolwell, Snehal G. Thakkar, Tyler Y. Kang
Publikováno v:
Bone marrow transplantation. 46(2)
The standard approach for relapsed diffuse large B-cell lymphoma (DLBCL) involves auto-SCT. However, studies that established this approach were conducted before the inclusion of rituximab (R) with first-line therapy became routine. Whether DLBCL pat
Publikováno v:
Renal Cell Carcinoma ISBN: 9781588297372
Metastatic renal cell carcinoma (RCC) is a tumor refractory to standard cytotoxic chemotherapy regimens. The rationale for the use of cytokines in this cancer is based upon compelling evidence that RCC is sensitive to immunological manipulation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0bdad2252d219b6440172bfaa1f51f55
https://doi.org/10.1007/978-1-59745-332-5_4
https://doi.org/10.1007/978-1-59745-332-5_4